Payer Insights: RA : Bulletin #2 [Report Updated: 01-06-2017]
Published by FirstWord Pharma: 01 Jun 2017 | 107167 | In Stock
This edition presents payer views on recent developments in the rheumatoid arthritis (RA) market. Topics include; recent positive opinion from the European Medicines Agency (EMA) for Regeneron/Sanofi’s Kevzara (sarilumab); recent approvals of biosimilar Enbrel and biosimilar Humira in the EU; and Eli Lilly/Incyte’s Olumiant (baricitinib) gaining marketing authorisation in the EU.
How do payers intend to cover sarilumab? Will there be any restrictions?
Is sarilumab likely to be utilised as a first or second-line therapy?
What factors will determine the incorporation of sarilumab in formularies? What role will drug pricing and treatment guidelines play?
Will biosimilars of Enbrel and Humira capture market share from branded anti-TNFs?
Will the availability of biosimilar anti-TNFs improve patient access to RA treatment?
What role will payers play in switching patients to biosimilar anti-TNFs?
What patient subset will be targeted for switching to biosimilar anti-TNFs?
On what factors will the uptake of biosimilars be dependent on?
Will payers prefer biosimilars of Enbrel over biosimilars of Humira?
How are biosimilars of Remicade viewed by payers?
Are payers surprised that baricitinib was declined approval in the US, but not in the EU?
How important will discounts on baricitinib be for making reimbursement decisions?
Will the RA treatment paradigm shift towards oral and/or biosimilar agents?
Table of Contents
for Payer Insights: RA : Bulletin #2 [Report Updated: 01-06-2017]
|Title||Date Published||Price from||More Details|
|Biosimilars: US Payer Perspectives|
IntroductionBiosimilars: US Payer Perspectives pulls back the curtain on the US biologics market and...
|01 Apr 2015 by FirstWord Pharma||USD $2,195||More Info|
|Harnessing the Power of Patient Support Programmes: pharma, patient and payer perspectives|
IntroductionIt all started years ago, with a few patients asking questions on the internet. These da...
|01 Apr 2015 by FirstWord Pharma||USD $695||More Info|
|Payer Perspectives on Risk Sharing Deals|
IntroductionRisk sharing agreements have been a strategic tool employed for more than a decade. Yet,...
|01 Mar 2015 by FirstWord Pharma||USD $695||More Info|
|Physician Views: Do cardiologists agree with payer rhetoric on PCSK9 inhibitors?|
Scope Last week, CVS Health became the second pharmacy benefit manager (PBM) to publicly highlight t...
|25 Feb 2015 by FirstWord Pharma||USD $695||More Info|
|Biosimilars: European Payer Perspectives|
IntroductionCost is king when it comes to European biosimilars. One issue unites European healthca...
|06 Jan 2015 by FirstWord Pharma||USD $2,195||More Info|
|Orphan Drug Market Access: Payer Insights on the Present and Future|
IntroductionOrphan Drug Market Access: Payer Insights on the Present and Future is a report that exa...
|14 Oct 2014 by FirstWord Pharma||USD $695||More Info|
|Patient Assistance Programs: Payer and Pharma Perspectives|
IntroductionPatient assistance programs (PAPs) are evolving in response to increasingly restrictive ...
|02 Oct 2014 by FirstWord Pharma||USD $695||More Info|
|Payer Insights: Hepatitis C|
IntroductionThe race is on for the company that can competitively price treatment regimens, share da...
|26 Sep 2014 by FirstWord Pharma||USD $7,900||More Info|
|Oncology Market Access Europe – Payer and Industry Perspectives|
IntroductionOncology Market Access Europe – Payer and Industry Perspectives answers your questions:W...
|03 Jul 2014 by FirstWord Pharma||USD $995||More Info|
|Pharma and the Changing US Payer Environment: Meeting the demands of Accountable Care Organizations (ACOs)|
IntroductionThere’s a revolution happening...and it’s going to change the way pharma thinks. As the ...
|01 Nov 2013 by FirstWord Pharma||USD $695||More Info|
This report is published by FirstWord Pharma
Download Free Report Summary PDF
Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.
Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.
Accepted Card Types
Buy now using our secure payment system.